{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-26-000005","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.961510+00:00","generated_at":"2026-05-16T07:02:36.415961+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's","bullets":["FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.","Phase 1b registrational study to start; site and regulatory activities in Australia underway.","FDA alignment on 505(b)(2) NDA pathway provides clear development path for SER-252.","CEO Steve Ledger calls milestone a major step toward addressing significant unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-26-000005","json":"https://secwatch.observer/filing/0001708599-26-000005.json","markdown":"https://secwatch.observer/filing/0001708599-26-000005.md","text":"https://secwatch.observer/filing/0001708599-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000005/0001708599-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000005/ser-20260127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:02:36.415961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}